Evidence map›Paper›PMID 21104044›Full record

ReviewCurrent osteoporosis reports2011

Oral contraceptive use and bone.

Shuying Wei, Tania Winzenberg, Laura L Laslett, Alison Venn, Graeme Jones

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current osteoporosis reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Premenopausal Osteoporosis.Endocrinology and metabolism clinics of North America · 2017
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuying WeiMenzies Research Institute, University of Tasmania, Private bag 23, Hobart, Tasmania 7000, Australia. Shuying.Wei@utas.edu.au
Tania Winzenberg
Laura L Laslett
Alison Venn
Graeme Jones

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sex hormones play a key role in bone homeostasis, and oral contraceptive (OC) use may affect bone mass in women. However, the nature of the association between OC use and bone remains controversial. This paper critically reviews studies on OC use and bone published between January 2009 and August 2010. Studies of OC use and bone mass mainly focus on adolescents or young adults and showed mixed results. Weak evidence suggests that OC use has no effect or a beneficial effect on bone mass, except in women commencing OCs shortly after menarche, and a consistently negative effect on bone turnover markers. A limited number of studies have examined the effect of ultra-low-dose OC (20 μg ethinyl estradiol) on bone mass in adolescents or young adults, and present conflicting results. The lack of randomized trials indicates that further high-quality prospective studies are required to investigate the effect of OC use on bone mass, particularly the optimal dose and timing of initiation of OC use in adolescents requiring contraception.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersBone DensityClinical Trials as TopicCollagen Type IContraceptives, OralFemaleHumansMiddle AgedOsteocalcinOsteoporosisPeptidesTime FactorsBiomarkersCollagen Type Icollagen type I trimeric cross-linked peptideContraceptives, OralOsteocalcinPeptides

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.